Spruce Biosciences Inc

NASDAQ:SPRBUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Yesterday

Show headlines and story abstract

• Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Monday May 13, 2024 by Dow Jones

  4:01PM ET on Monday May 13, 2024 by Dow Jones
  Companies Mentioned: SPRB
  
  Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the design, results, conduct, progress and timing of Spruce's clinical trials; Spruce's expectations regarding reporting results of its clinical trials in 2024; Spruce's plans to meet with the FDA to discuss the potential registrational path forward of tildacerfont for adult and pediatric classic CAH; upcoming investor conferences; and Spruce's product candidate, strategy and regulatory matters. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipate", "will", "potential", "suggest", "plan" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce's filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
  

• *DJ Spruce Biosciences 1Q Loss/Shr 28c >SPRB, from 4:01PM ET on Monday May 13, 2024 by Dow Jones

  4:01PM ET on Monday May 13, 2024 by Dow Jones
  Companies Mentioned: SPRB

• Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Monday May 13, 2024 by Business Wire

  4:01PM ET on Monday May 13, 2024 by Business Wire
  Companies Mentioned: SPRB

  --Posters Highlighting Baseline Characteristics from the CAHmelia Program in Adult CAH and CAHptain-205 Study in Pediatric CAH Presented at the Pediatric Endocrine Society (PES) 2024 Annual Meeting

  --Topline Data from the CAHmelia-204 Study in Adult CAH and Additional Dose-Ranging Data from Adults and Children with CAH in CAHptain-205 Anticipated in Q3 2024